Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company's scientific presentations from the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting taking place from May 30 to June 3, 2025, in Chicago, Illinois.
'In metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617, comprehensive epigenomic profiling of plasma not only captured PSMA expression, but also revealed that elevated Wnt signaling and reduced immune activity at baseline were associated with inferior outcomes,' said Jacob E. Berchuck, MD, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University. 'These findings highlight the potential of this approach to provide novel insights into molecular correlates of therapeutic response and resistance.'
'Plasma-based comprehensive epigenomic profiling enables high-resolution characterization of tumor-intrinsic transcriptional programs and resistance pathways. In this study, we applied this approach to HR+/HER2- metastatic breast cancer patients treated with sacituzumab govitecan with or without pembrolizumab, revealing distinct immune and proliferative pathways associated with therapeutic response,' said Ana C. Garrido-Castro, MD, Medical Oncologist, Dana-Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School. 'These findings could guide future trial designs by informing selection of combination versus monotherapy strategies based on underlying tumor biology.'
'Our ASCO presentations underscore the potential of the Precede Bio platform to decode the transcriptional biology underlying response and resistance to two leading next-generation precision therapies,' said Carl Barrett, Chief Scientific Officer of Precede Bio. 'What sets our platform apart is its ability to deliver this level of biological insight through a minimally invasive and highly interpretable approach. We are excited to continue collaborating with drug developers and academic leaders to help guide the development and application of emerging precision medicines—including drug-, radio-, and immune-conjugates.'
Data presented at the ASCO Annual Meeting can be found in the presentations section of the company website and below:
Robust characterization of response & resistance to 177Lu-PSMA-617 in mCRPC by plasma-based epigenomic profiling
Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer
About Precede Biosciences
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind disease at any given moment, researchers and clinicians can better target medicines to the right patients in both drug development and clinical practice. Precede Bio seeks to improve success rates in drug development and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and therapy that is precise to the biology of their disease. Precede Bio's platform is available to drug developers and academic researchers. To learn more, visit www.precede.bio or follow us on LinkedIn.
Media Contact:
Donelle M. Gregory
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
21 minutes ago
- Bloomberg
EU-US Trade Talks Could Extend Beyond Trump's Deadline
Welcome to the Brussels Edition, Bloomberg's daily briefing on what matters most in the heart of the European Union. Trade talks between the EU and the US have intensified over the past week, aiming to secure at least a preliminary deal before Washington imposes a 50% tariff on nearly all EU exports. The best-case scenario would be agreement on the principles of an accord by July 9. Yet, we're told European officials believe negotiations sealing the deal in full could extend beyond President Donald Trump's deadline. Officials in Brussels remain cautious. While talks are taking place in a positive environment, they remain difficult — the EU believes the US is seeking one-sided concessions. US Commerce Secretary Howard Lutnick yesterday poured cold water on hopes for a swift accord, telling CNBC yesterday that Washington is prioritizing other partners and an agreement with the EU is likely to be the very last one that the US completes.
Bloomberg
43 minutes ago
- Bloomberg
Manhattan Renters Already Paying Record Prices Face More Hikes
Manhattan apartment rents reached yet another all-time high last month and are expected to keep rising as the market's most competitive season collides with the city's new broker-fee law. The median rent on new leases signed in May was $4,571, according to appraiser Miller Samuel Inc. and brokerage Douglas Elliman. It was the third record price reached in the past four months and exceeded the previous peak by $71.
Digital Trends
43 minutes ago
- Digital Trends
SpaceX Starlink rivalry grows as next Kuiper deployment nears
Amazon is about to send another batch of Project Kuiper internet satellites to orbit as it seeks to take on SpaceX's Starlink service to provide broadband internet to customers around the world. The tech giant has a long way to go before it has any hope of effectively challenging Starlink, but with its second launch set for next week, progress is being made toward its goal. Recommended Videos Project Kuiper is currently targeting Monday, June 16, for the launch of 27 internet satellites aboard a United Launch Alliance (ULA) Atlas V rocket from Cape Canaveral in Florida. The KA-02 mission comes seven weeks after the first Project Kuiper launch, which also deployed 27 internet satellites. Commenting after the inaugural launch, Rajeev Badyal, vice president of Project Kuiper, said: 'We've designed some of the most advanced communications satellites ever built, and every launch is an opportunity to add more capacity and coverage to our network.' SpaceX began deploying its Starlink internet satellites six years ago and now has more than 7,000 of them in low-Earth orbit, bringing broadband connectivity to more than 5 million customers globally. Project Kuiper says its initial constellation will be made up of more than 3,200 satellites, with more than 80 missions needed to reach that goal. To that end, Amazon has put together a busy launch schedule, with six additional satellite deployments planned for ULA's Atlas V rocket, at least 38 on ULA's Vulcan Centaur rocket, and dozens more with Arianespace and Blue Origin. SpaceX's workhorse Falcon 9 rocket may even help out. Amazon is targeting as early as the end of this year for the launch of a high-speed, low-latency satellite-powered internet service, with as few as 1,000 satellites needed for global coverage. Building out the constellation to the targeted 3,200 satellites will help to boost network performance and reliability for paying customers.
